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A B S T R A C T   
This study investigated the clinical management of non small cell lung cancer (NSCLC) patients during the first 
wave of coronavirus disease 2019 (COVID-19) outbreak in Italy. A 29-questions survey was sent to 95 Italian 
thoracic oncologists, with 77 % of them declaring significant changes in the outpatients management and 
treatment. The results of this survey pointed out a significant delay of lung cancer diagnosis along with a relevant 
reduction of patients’ accrual within clinical trials. Telemedicine emerged as a valid support for patient- 
healthcare interactions. Therapeutic indications followed the guidelines for adjuvant chemotherapy and con-
current chemo-radiation. Clinical indications to first-line therapies were largely confirmed, while major changes 
regarded the selection of second line treatment options as well as the management of elderly population. 
This work may represent a valid source of information to improve the clinical management of NSCLC patients 
during second wave of COVID-19 pandemic.   
1. Introduction 
At the end of 2019, a novel viral pneumonia caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported at 
Wuhan, China (Guan et al., 2020). Since then, the related coronavirus 
disease 2019 (COVID-19) syndrome, has progressively involved coun-
tries outside China leading the World Health Organization (2020) to 
declare the state of pandemic on 11th March 2020. Since the initial 
detection of the virus, more than 48 million cases and more than 
1.200.000 deaths from COVID-19 have been confirmed worldwide 
(WHO website, 2020). Italy has been one of the most affected countries 
with, as of 7th November 2020, 809.000 confirmed COVID-19 cases and 
48.000 deaths, according to the National Institute of Health (ISS,‘Istituto 
Superiore di Sanità, 2020) data (ISS website, 2020). 
In this challenging situation, the oncological community was called 
to protect cancer patients, considered one of the most vulnerable pop-
ulation, due to coexisting chronic diseases, overall poor health status, 
type of infection and systemic immunosuppressive condition caused by 
both cancer and anticancer therapies (Kuderer et al., 2020). In this 
regard, the Italian Association of Medical Oncology (AIOM) has pro-
posed specific recommendations to optimize the clinical management of 
patients and to regulate the access of both patients and caregivers to the 
hospitals, in order to encourage a careful evaluation of risk/benefit ratio 
case by case and, ultimately, minimize the risk of infection (AIOM 
website). Accumulating evidence suggest that lung cancer patients are 
more susceptible to infection since they are usually elderly and smokers, 
with poor nutritional status and compromised lung function. Several 
studies have already shown a higher risk of COVID-19 related compli-
cations in non-small cell lung cancer (NSCLC) patients, often related to 
their immunocompromised status (Rogado et al., 2020). Based on these 
evidences, the European Society for Medical Oncology (ESMO) has also 
provided management and treatment recommendations for NSCLC pa-
tients adapted to the COVID-19 era (Passaro et al., 2020). In this com-
plex landscape, characterized by the recent occurrence of a second 
pandemic wave worldwide, where the emergency evolution continues to 
be uncertain and clinical decisions persistently difficult, sharing opin-
ions and behaviors is of paramount importance to find new common 
“horizons” in the clinical management of NSCLC, and ultimately ensure, 
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the best care to our patients. Based on these considerations, here we 
report the results of a national Italian survey carried out on April 2020, 
aiming to evaluate the clinical management of NSCLC patients and ul-
timately provide a reliable picture of real-word practice during the 
emergency of COVID-19. 
2. Materials and methods 
An online (Google_ form) survey (Supplementary Material) was 
developed by a group of thoracic oncologists working at the San Luigi 
Gonzaga Hospital, Orbassano (Turin), and distributed to different 
thoracic oncologists, across the different Italian regions. The online 
answers were systematically collected from the 12th of April 2020, until 
the 2nd of May 2020. 
The current survey aimed to investigate the impact of COVID-19 
outbreak on the attitudes and practice of thoracic oncologists in their 
clinical management of NSCLC patients. 
The survey was confidential and anonymous and included four 
different sections, exploring the following topics: general questions 
about demographic and employment details of respondents (Q1-Q4); 
outpatient management of NSCLC patients (Q5-Q10); therapeutic de-
cisions from the pandemic declaration to the following four weeks 
(March 11th -April 11th 2020) (Q11-Q21); clinical management of 
NSCLC patients with suspected or confirmed COVID-19 infection 
(Q22− 23). Twenty-nine questions have been drawn up with multiple 
and single answers admitted for 17 and 12 questions, respectively. 
Descriptive statistics were used to summarize the data. Categorical 
variables were summarized as counts and percentages. 
3. Results 
The online survey was distributed to 95 thoracic oncologists from all 
over Italian Regions. A total of 79 responses were received, with an 
overall response rate of 83 %. The majority of responders (60) usually 
manage between 150–200 new cases of NSCLC patients per year. The 
general characteristics of responders are shown in Supplementary table. 
3.1. Outpatient/Day hospital management of NSCLC patients 
The majority of oncologists (77.3 %) declared a significant change in 
the outpatient/day hospital management of NSCLC patients during the 
COVID-19 emergency (Fig. 1A). In most cases (97.5 %), triage of pa-
tients, always including body temperature measurement, was regularly 
performed before entering the hospital and/or the Medical Oncology 
Unit. (Fig. 1B). As compared to the pre− COVID-19 emergency period, 
the number of consultations in case of suspected NSCLC diagnosis 
decreased in about half of cases (46.8 %), with a major reduction when 
considering the number of patients coming from the emergency 
department, as reported in about 60 % of cases (Fig. 1C and D). As 
consequence, the total number of patients with any stage, newly diag-
nosed NSCLC, within the observational period, was reported to be lower 
than the pre-pandemic era by the 55.7 % of oncologists (Fig. 1E). 
Interestingly, multidisciplinary tumor boards were delayed or per-
formed virtually in about half of cases (48.1 %) (Fig. 1F). 
3.2. Treatment of NSCLC patients 
3.2.1. Early and locally advanced disease 
We asked physicians to consider their therapeutic indications for 
patients with stage I-III NSCLC, from the pandemic declaration to the 
following four weeks (March 11th -April 11th 2020) in comparison to 
the pre− COVID-19 period. As for chemotherapy administrated with 
adjuvant intent, clinical therapeutic indications did not change for the 
majority of responders (62 %) (Fig. 2A). Likewise, for the treatment of 
unresectable locally advanced disease, most of the Italian thoracic on-
cologists (72.2 %) confirmed, in accordance with available guidelines, 
the unchanged indication to concomitant chemoradiation. However, a 
significant subgroup (25.3 %) of colleagues declared their preference for 
the sequential strategy, because they consider this approach safer in 
terms of pulmonary toxicity (Fig. 2B). 
3.2.2. First-line therapy 
Physicians reported their clinical indications to the different first line 
treatment options during the COVID-19 pandemic. As regards chemo-
therapy, the majority of them (81 %) declared that neither treatment 
recommendations were modified nor ongoing therapies were sus-
pended. (Fig. 2C). Similarly, clinical indications to first-line immuno-
therapy alone or in combination with chemotherapy remained 
unchanged for 78.5 % and 82.3 % of responders, respectively (Fig. 2D, 
E). However, the 17.7 % of them declared to have delayed the beginning 
of immune-based treatments as far as possible (Fig. 2D,E). As for 
frontline tyrosine kinase inhibitors (TKIs), almost all responders (96.2 
%) confirmed that their clinical indication did not change, while only 
7.6 % modified the therapeutic schedule of TKI administration (Fig. 2F). 
In elderly patients (over 75 years) with non-oncogene-addicted meta-
static NSCLC and potentially candidate to first line therapy (chemo-
therapy or immunotherapy), therapeutic indications were subjected to 
relevant changes in the majority of cases, with about 33 % of colleagues 
declaring a significant decrease of treatment prescription and 27.8 % of 
them preferring alternative, less toxic schedules, or oral drugs, in order 
to reduce hospital accesses, and consequently risk of infection (Fig. 2G). 
Maintenance therapy with pemetrexed has been regularly administered 
from the majority of oncologists, but free-interval between administra-
tions has been frequently prolonged by one week (44.3 % of cases) 
(Fig. 2H). Similarly, as regards first-line immunotherapy, a significant 
percentage of oncologists declared to have prolonged the free-interval 
between treatment administrations (42 %), to have suspended ongoing 
therapy in high-risk patients (19 %), and to have definitively dis-
continued treatment in case of partial or complete response confirmed at 
the last computed tomography (CT) as well as in cases of long-term 
disease control (> 18 months of treatment) (15.2 %) (Fig. 2I). 
3.2.3. Second-line therapy 
The management of second line treatment, including either chemo-
therapy or immunotherapy was subjected to relevant changes for most 
of responders (59 %), with about half of them declaring their preference 
for alternative schedules/drugs characterized by low toxicity profile 
and/or oral administration. In the remaining cases, treatment was dis-
continued in high-risk subgroups, like elderly or patients with multiple 
comorbidities. As for second line immunotherapy, schedule of treatment 
has been modified or suspended in high risk patients in 27 % of cases and 
25 % of oncologists declared to have discontinued treatment in case of 
partial or complete response confirmed at the last CT scan or in case of 
achievement of more than 18 months of treatment (Fig. 2L,M). About 40 
% of oncologists declared as the tendency to discontinue any active 
second-line treatment in favor of best supportive care (BSC) was slightly 
increased during the first wave of COVID-19 pandemic (Fig. 2N). For 
patients in follow up (out of any active treatment), a telemedicine 
approach through phone calls or emails was preferred by 78.5 % of re-
sponders. Finally, as regards clinical cancer research during the COVID- 
19 outbreak, the majority of oncologists (79.7 %) declared that the 
accrual of lung cancer patients within clinical trials decreased by more 
than 50 % (Fig. 2O,P). 
3.3. Clinical management of NSCLC patients with suspected COVID-19 
In case of suspected COVID-19 infection in NSCLC patients, in the 
majority of cases the nasopharyngeal swab was performed at the 
Emergency Department (60 %), followed by the Medical Oncology Unit 
(39 %) or general practitioners (37 %) (Fig. 3A). The majority of on-
cologists (73 %) declared to have had less than 5 NSCLC patients or none 
affected by COVID-19 infection at their Institution, within the 
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Fig. 1. Schematic representation of the responses to the following survey’s 
questions: A Has the outpatient/Day Hospital organization for the management 
of NSCLC patients changed? B Where NSCLC patients underwent triage (body 
temperature measurement, questions about epidemiological status and clinical 
conditions)?. C Did the the number of consultations in patients with suspected 
NSCLC diagnosis vary?. D Did the number of consultations in patients with 
suspected NSCLC diagnosis coming from emergency department vary?. E Did 
the number of patients with newly diagnosed of NSCLC vary?. F Has multi-
disciplinary tumor boards for the discussion of NSCLC patients management 
been manteined?.   
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observational period (Fig. 3B). The characteristics of COVID-19 infec-
tion management and outcomes in NSCLC patients were reported in 
Table 1. 
4. Discussion 
In general, the results of this survey highlighted as both management 
and treatment strategies of NSCLC patients have been profoundly 
modified after the COVID-19 outbreak. Particularly, the reduction of the 
total number of novel NSCLC diagnoses, partially ascribed to the sig-
nificant decrease of patients with suspected lung cancer coming from the 
emergency department, certainly represents one of the most relevant 
aspects to be adequately addressed. A recent paper, published by Din-
mohamed et al., showed also a significant decrease of cancer diagnoses 
in the Netherlands, when compared to the pre− COVID-19 emergency 
period (Dinmohamed et al., 2020). Specifically, between the 6th of 
January 2019 and the 12th of April 2020 the relative change in lung 
cancer diagnoses was reported to be around 30–40 %. This evidence has 
been partially explained by the lower access of individuals with 
non-specific cancer symptoms to their general practitioner, leading to a 
subsequent delay of clinical investigations. Furthermore, several hos-
pitals primarily involved in the COVID-19 emergency, have had post-
poned diagnostic evaluation, while national screening programs for 
early diagnosis of breast, colorectal and cervical cancers have been 
temporarily halted. The ministerial decrees, which placed Italy under 
COVID-19 lockdown, forced all Regions to temporally suspend both first 
level examinations and screening programs, with potential relevant 
consequences in terms of health and social costs, which will likely 
emerge in the upcoming months. Despite the emergency status, the 
majority of Italian medical oncologists maintained their clinical in-
dications to adjuvant treatments and to concurrent chemo-radiotherapy 
for NSCLC patients with resected and locally advanced disease, respec-
tively. These data reflect the recommendations published by ESMO with 
three grades of priority (high, medium and low) based on the magnitude 
Fig. 2. Schematic representation of the responses to the following survey’s questions: A Has the indication to adjuvant treatment been modified for surgically 
resected NSCLC patients? B Has the indication to concurrent chemo-radiotherapy been modified for NSCLC patients with unresectable locally advanced disease?. C 
Has the indication to first-line chemotherapy been modified for patients with metastatic NSCLC?. D Has the indication to first-line chemo-immunotherapy been 
modified for patients with metastatic NSCLC?. E Has the indication to first-line single agent immunotherapy been modified for patients with metastatic NSCLC?. F 
Has the indication to first-line targeted therapies been modified for patients with metastatic NSCLC? G Has treatment indication to first line chemotherapy or 
immunotherapy been modified in elderly patients (over 75 years) with non-oncogene addicted metastatic NSCLC?. H Has treatment indication to manteinance 
therapy benn modifed for patients with metastatic NSCLC candidate to start/continue maintenance chemotherapy (pemetrexed). I Has treatment indication for 
metastatic NSCLC patients undergoing first line immunotherapy been modified?. L Has treatment indication to second line chemotherapy been modified fro met-
astatic NSCLC patients?. M Has treatment indication to second line immunotherapy been modified for metastatic NSCLC patients?. N Has the indication to interrupt 
active treatment and start best supportive care been modified in metastatic NSCLC patients?. O Has follow-up management for NSCLC patients been modified?. P Has 
NSCLC patients’ accrual in ongoing clinical trials been modified?. 
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Fig. 2. (continued). 
Fig. 3. Schematic representation of the responses to the following survey’s questions: A In case of suspected COVID-19 infection in NSCLC patients, where the 
nasopharyngeal swab has been performed?. B How many NSCLC patients have been positive for COVID-19 infection in your Institution considering the period from 
the pandemic declaration to the following four weeks (March 11th-April 11th 2020)?. 
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of overall survival (OS) gain and improvement of quality of life (QoL) 
(Passaro et al., 2020). Particularly in the early stages, the high priority is 
related to the administration of adjuvant chemotherapy in T3/4 N2 for 
young (<65 years) and fit patients. Similarly, concomitant or sequential 
chemo-radiotherapy for unresectable NSCLC stage III has been pre-
scribed without delay. For metastatic patients, there was a general 
consensus among the interviewed oncologists to not delay first-line 
therapies. ESMO guidelines also highlighted the high priority for ther-
apeutic options in the metastatic setting to maintain survival benefit, 
along with cancer-related symptoms and QoL control. The final decision 
should be performed at single patient level, taking into account different 
factors, like patients’ clinical conditions (age, comorbidities, symp-
toms), disease’s pathological/molecular characteristics and treatments 
implications, including the number of hospital accesses required by 
treatment schedules, carefully balancing both predictable and unpre-
dictable side effects. Despite the risks of toxicity associated with 
immune-checkpoint inhibitors were not well known during the first 
wave of COVID-19 emergency, a large fraction of oncologists declared to 
have spread the free-interval between treatment administrations both in 
first, and second line setting; to have suspended ongoing therapy in 
high-risk patients and to have definitively discontinued treatment in 
case of long-term clinical benefit. In this context, some preliminary ev-
idence suggested that the frequency of severe illness and hospitalization 
was higher in cancer patients treated by immunotherapy, but the low 
number of patients included limited any definitive conclusions or 
changes in our current treatment practice (Robilotti et al., 2020). 
Moreover, a recent paper evaluated the impact of the programmed 
death-1 (PD-1) blockade on the severity of COVID-19 infection in NSCLC 
patients. The authors pointed out that PD-1 inhibition was not associ-
ated with an increased risk of severity of COVID-19 infection in patients 
with lung cancers (Luo et al., 2020). In the upcoming months, preclinical 
and clinical data will likely help oncologists to clarify the link between 
COVID-19 infection and possible worse outcome for NSCLC patients 
treated with immunotherapy. Another relevant aspect emerging from 
this survey regards the clinical management of elderly population, 
almost characterized by a significant reduction of first-line treatment 
prescriptions, including a therapeutic shift to alternative, less toxic 
schedules or oral drugs, in order to minimize their access to Oncology 
Departments. A multidisciplinary assessment by the Comprehensive 
Geriatric Assessment (CGA) emerged as an important tool during this 
emergency, to plan both medical and social health care for every patient 
(Passiglia et al., 2020). As for the follow-up visits, this survey pointed 
out that most of oncologists performed their clinical consultations by 
mails, phone call and/or web virtual meetings. This strategy has been 
supported by the AIOM statement, recommending a telemedicine 
follow-up approach in order to perform a quick triage of the clinical 
condition, and allowing the examination of laboratory and/or imaging 
exams. Another major issue regards clinical research activities during 
the COVID-19 pandemic, characterized by a dramatic decrease of pa-
tients’ accrual within clinical trials, with a relevant impact on the 
quality of care to be offered to our patients. Similarly, the management 
of patients already enrolled within a clinical trial may have undergone 
changes during this emergency time. Therefore, to face this risk, the 
Food and Drug Administration (FDA) (2020), the European Medicines 
Agency (EMA) (2020) and the Italian Medicines Agency have issued 
special guidance for the conduction of clinical trials during the 
COVID-19 emergency (Agenzia Italiana del Farmaco (AIFA), 2020). 
Finally, this survey showed a small snapshot of NSCLC patients with 
COVID-19 infection. Most of oncologists had less than 5 patients infected 
by COVID-19, generally treated with hydroxychloroquine and antiviral 
therapy. Several evidences have showed a proportion of asymptomatic 
COVID-19 patients that play a critical role as source of transmission to 
cancer patient (Bai et al., 2020). Therefore, it is important to consider 
NSCLC patients as a specific population to be priority tested due to the 
increased risk of complications caused by older age, significant cardio-
vascular and respiratory comorbidities and smoking-related lung dam-
age. In this pandemic scenario, the use of liquid biopsy might be 
implemented in order to reduce the risks of COVID-19 infection for 
NSCLC patients by limiting their access to the oncology departments 
(Rolfo et al., 2020) The proposed diagnostic approach might be practice 
changing even in the upcoming months when COVID-19 outbreak will 
be under control. 
5. Conclusions 
In conclusion, this survey provides a real-word “picture” of the 
clinical management of NSCLC patients in Italy during first wave of 
COVID-19 emergency. Although the majority of Italian thoracic oncol-
ogists have proven to follow both national and international treatment 
guidelines even during this difficult period, however major concerns 
regarded the selection of second or further lines of treatment as well as 
the clinical management of elderly population, characterized by a 
potentially unfavorable risk/benefit ratio. The most relevant issues 
emerging from this survey included the significant delay of lung cancer 
diagnosis and the dramatic decrease of patients’ accrual within clinical 
trials, while telemedicine demonstrated to be a valid support to facilitate 
patient-healthcare interactions. 
These data should be keep in mind in the upcoming months, char-
acterized by the second wave of COVID-19 pandemic, in order to pro-
vide right solutions to the emerging criticisms and ultimately improve 
the worldwide clinical management of NSCLC patients. 
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20− 50% 7 (13.7 %) 
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